At the Extraordinary General Meeting (the "EGM") in IMMUNICUM Aktiebolag (publ) on 18 May 2016, the shareholders adopted the resolutions summarized below:
The EGM resolved to carry out a rights issue of shares with preferential rights for shareholders in accordance with the proposal of the Board of Directors. The EGM also resolved to authorize the Board of Directors to, in the event the rights issue is oversubscribed, resolve on a rights issue of additional shares (overallotment option) in accordance with the proposal of the Board of Directors. For more information about the planned capital raising, please refer to the press release published on 25 April 2016.
The EGM further resolved to authorize the Board of Directors, on one or several occasions during the period until the next AGM, with or without deviation from the shareholders' preferential rights, to resolve on a rights issue of not more than 5 040 000 shares.
The EGM finally resolved to adopt guidelines for executive remuneration in accordance with the proposal of the Board of Directors.
For further information, please visit www.immunicum.com.
Jamal El-Mosleh, CEO, Immunicum
Phone: +46 (0) 31 41 50 52
jamal.el-mosleh@immunicum.com
The company's Certified Adviser is Redeye AB
Phone: +46 (0) 8 545 013 31. www.redeye.se